AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02053610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Study NCT02053610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
Study NCT02053610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
Study NCT03270800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA control
Description: Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
Study NCT03270800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMX101 vaccine
Description: Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
Study NCT01985815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VC/VS stimulation
Study NCT00337753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 5-weeks of Cognitive Behavioral Therapy
Study NCT00337753 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list
Description: subjects assigned to wait-list condition for six-weeks
Study NCT03504345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometrium
Description: The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
Study NCT03504345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prometrium
Description: The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
Study NCT00374751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium (153SM)
Description: The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
Study NCT03184779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ski and Snowboard Safety Video
Description: The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
Study NCT02097771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SupremeTM
Study NCT02738528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice and brushing guidance in patients with Parkinson Disease
Study NCT01798979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
Study NCT01798979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
Study NCT01762969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modification based on molecular response at 3 months
Description: Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
Study NCT02385383 — intervention group
Intervention type: DRUG
Intervention: Iron-III Isomaltoside 1000
Description: Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
Study NCT02097771 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AuraOnceTM
Study NCT03110081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: Quadratus lumborum (QL) block for open partial nephrectomy.
Study NCT03110081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia for open partial nephrectomy.
Study NCT00571116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Given PO
Study NCT00571116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Given IV
Study NCT00441038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Guide
Description: Education on postural hygiene and handout of The Back Guide
Study NCT00441038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Back Book
Description: Education on active management and Handout of The Back Book
Study NCT00441038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and general health
Description: Education on cardiovascular and general health
Study NCT02385383 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: Standard Care in a historical control cohort
Study NCT02855736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about.
Study NCT02855736 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (food journal)
Description: Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day.
Study NCT00531622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saredutant (SR48968)
Description: oral administration, capsules
Study NCT00531622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration, capsules
Study NCT00531622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral administration, capsules
Study NCT00531622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration, capsules
Study NCT00531622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: oral administration, capsules
Study NCT01517204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope (Macintoish laryngoscope)
Description: Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
Study NCT01517204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trachway(R) intubating stylet
Description: Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
Study NCT04029805 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study NCT04029805 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study NCT02094898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.3 mg/kg/hr of ketamine infused for 100 minutes
Study NCT01982799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: placebo
Study NCT01432626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Description: All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
Study NCT01124097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.
Study NCT01124097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets will be used.
Study NCT02039648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rumex acetosa L. extract
Study NCT02039648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01275599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
Study NCT01275599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
Study NCT04451447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.
Description: The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
Study NCT04451447 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline test (routine test)
Description: The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
Study NCT00703183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: administered as a single dose, orally
Study NCT00703183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: administered as a single dose, orally
Study NCT01306123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nascobal nasal spray (cyanocobalamin, USP)
Description: Single intranasal administration
Study NCT01306123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12-ratiopharm N, injection solution
Description: One single intramuscular administration
Study NCT00648687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suck 12.5% dextrose in water 5 minutes before the procedure
Description: Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
Study NCT02667106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX0041-2
Description: Pharmacokinetic study
Study NCT02865551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Extended bladder catheterization after epidural anesthesia.
Study NCT02865551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short term catheter
Description: Intermittent catheterization every 4 hours after epidural anesthesia.
Study NCT02865551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Performance of epidural anesthesia by a certified anesthesiologist.
Study NCT02790879 — intervention group
Intervention type: OTHER
Intervention: Transition pediatric - adult
Study NCT00126659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo cytoreductive nephrectomy
Study NCT00126659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00126659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04636645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal treadmill
Description: Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
Study NCT04636645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill with lower limb positive pressure
Description: Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
Study NCT01982799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Description: Ibuprofen
Study NCT01982799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naproxen
Description: naproxen
Study NCT04636645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill with without lower limb positive pressure
Description: Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
Study NCT02097186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
Study NCT02980523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-157
Description: PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
Study NCT02980523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox
Description: Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
Study NCT02980523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymar®
Description: Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
Study NCT02980523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
Study NCT02980523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lagricel Ofteno®
Description: Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
Study NCT02024295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademethionine
Description: ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
Study NCT02024295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyene Phosphatidyl choline
Description: Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
Study NCT02024295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademethionine
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
Study NCT02024295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ademethionine
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
Study NCT00676845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: dosage form: oral tablet; frequency: daily; duration: 52 weeks
Study NCT00676845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: tablet; frequency: daily; duration: 3 weeks
Study NCT00824330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Phase; Exercise Phase
Description: After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
Study NCT01783340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin capsules
Description: Azithromycin capsules will be administered at each immunization
Study NCT01783340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin capsules
Description: Azithromycin capsules will be administered at each immunization
Study NCT01783340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered at each immunization
Study NCT01783340 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization with falciparum
Description: three inoculations with 5 infected mosquito bites
Study NCT01783340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization with falciparum
Description: three inoculations with 5 infected mosquito bites
Study NCT02039245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC
Description: Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
Study NCT00577135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Q12 hour bolus
Description: Q12 hours bolus
Study NCT00577135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Continuous Infusion
Description: Continuous infusion
Study NCT00577135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-Low Intensification
Description: 1x oral dose
Study NCT00577135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide-High Intensification
Description: 2.5x oral dose
Study NCT01719510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~* one swab for GBS detection by real-time PCR~* the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~2. A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding.
Study NCT00633945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02392754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)
Description: The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
Study NCT02375347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chickpea Enhanced Diet (Short term)
Description: Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14.
Study NCT02552147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Study NCT02552147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal placebo
Study NCT03634397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less-Impaired Arm Training
Description: Participants receive virtual reality and manipulation training in their less impaired arm.
Study NCT03634397 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Contralesional Arm Comparison
Description: Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
Study NCT00730613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
Study NCT00730613 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: At the time of excess pathology samples documenting response/relapse
Study NCT00730613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: CSF generated at the time of each T-cell dose